Drug Trial Radar · NCT01155479
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
Last checked: Nov 20, 2026Latest source record: Nov 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,022
Actual
Start
Jul 6, 2010
Primary completion
Jul 16, 2013
Study completion Jul 16, 2013
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist. The purpose of Part 1 (first 26 weeks) is to determine if preladenant is effective in the treatment of early Parkinson's Disease. The purpose of Part 2 (second 26 weeks) is to determine if preladenant is safe and well tolerated. The primary efficacy hypothesis is that at least the 10 mg twice daily dose of preladenant is superior to placebo as measured by the change from Baseline to Week 26 in the sum of Unified Parkinson's Disease Rating Scale (UPDRS) Parts 2 and 3 scores (UPDRS2+3).
Conditions
- Parkinson Disease
Interventions
Preladenant 2 mg tabletDrug
Preladenant 2 mg oral tablet taken twice daily
Preladenant 5 mg tabletDrug
Preladenant 5 mg oral tablet taken twice daily
Preladenant 10 mg tabletDrug
Preladenant 10 mg oral tablet taken twice daily
Rasagiline 1 mg capsuleDrug
Rasagiline 1 mg oral capsule taken once daily
Placebo for Rasagiline 1 mg capsuleDrug
Placebo for rasagiline 1 mg oral capsule taken once daily
Placebo for PreladenantDrug
Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)Time frame: Baseline and Week 26
- Number of Participants With Adverse Events (AEs) in Part 1Time frame: Day 1 to Week 26
- Number of Participants Who Discontinued Study Due to an AE in Part 1Time frame: Day 1 to Week 26
- Number of Participants With Adverse Events (AEs) in Part 2Time frame: Week 27 to Week 52
- Number of Participants Who Discontinued Study Due to an AE in Part 2Time frame: Week 27 to Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.